APA (7th ed.) Citation

Jiao, B., Nyame, Y., Carlson, J., Garrison, L., & Basu, A. (2022). HSD7 Does Clinical Evidence of Heterogeneity Influence Treatment Selection? a Case Study of Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer. Value in Health, 25(7), S481. https://doi.org/10.1016/j.jval.2022.04.1009

Chicago Style (17th ed.) Citation

Jiao, B., Y. Nyame, JJ Carlson, LP Garrison, and A. Basu. "HSD7 Does Clinical Evidence of Heterogeneity Influence Treatment Selection? a Case Study of Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer." Value in Health 25, no. 7 (2022): S481. https://doi.org/10.1016/j.jval.2022.04.1009.

MLA (9th ed.) Citation

Jiao, B., et al. "HSD7 Does Clinical Evidence of Heterogeneity Influence Treatment Selection? a Case Study of Abiraterone Acetate for Metastatic Castration-Sensitive Prostate Cancer." Value in Health, vol. 25, no. 7, 2022, p. S481, https://doi.org/10.1016/j.jval.2022.04.1009.